不同评分系统在原发性肝癌肝动脉化疗栓塞术预后判断中的应用  

Application of different scoring systems in evaluating prognosis after transarterial chemoembolization for primary liver cancer

作　　者：汪晓芳 朱丽影[1] 卢宝玲[1] 钟丽华[1] 程昱[1] 樊健[1] 姚红[1] 于雷[1] 

机构地区：[1]哈尔滨医科大学附属第四医院传染科,哈尔滨150001

出　　处：《临床肝胆病杂志》2017年第10期2016-2020,共5页Journal of Clinical Hepatology

基　　金：国家科技重大专项经费资助(2014ZX10002002);黑龙江省博士后科研启动金资助(LBH-Q14115)

摘　　要：原发性肝癌治疗指南众多,其中巴塞罗那肝癌分期(BCLC)是国际上通常采用的肝癌治疗参考标准,然而只有B期符合肝动脉化疗栓塞术(TACE)的指征,限制了其临床应用。因此,近年来相继提出了评估原发性肝癌TACE治疗预后的评分系统,为原发性肝癌治疗提供重要参考。介绍了有关TACE治疗预后评分系统的应用现状,指出各评分系统的优缺点及评估效能,为肝癌治疗提供理论依据。There are many treatment guidelines for primary liver cancer,among which Barcelona Clinic Liver Cancer（ BCLC） is commonly used as the reference for the treatment of liver cancer in the world; however,only BCLC stage B patients meet the indication for transarterial chemoembolization（ TACE）,which limits the clinical application of TACE. Therefore,several scoring systems for evaluating prognosis after TACE have been developed in recent years and provide an important reference for the treatment of primary liver cancer. This article introduces the application of scoring systems for evaluating prognosis after TACE and points out their advantages/disadvantages and performance,in order to provide a theoretical basis for the treatment of liver cancer.

关 键 词：肝肿瘤 化学栓塞 治疗性 预后 综述 

分 类 号：R735.7[医药卫生—肿瘤]